Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
← catalyst calendarNCT07697456 · readout ≤ 1,899 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
2,000estimated
Sites
30
Countries
Australia, Belgium, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-24 | estimated | When the study began enrolling |
| Primary completion | Oct 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Crohn's Disease
- Ulcerative Colitis
Interventions
- Drug: Risankizumab — also filed as ABBV-066
- Drug: Trosunilimab — also filed as ABBV-382
- Drug: ABBV-701
Primary outcomes
what the primary-completion date above is the date OFCrohn's Disease Specific: Percentage of Participants Achieving Endoscopic Remission
measured At Week 28
Ulcerative Colitis Specific: Percentage of Participants who Achieve Endoscopic Remission
measured At Week 28
Number of Participants with Adverse Events (AEs)
measured Up to 98 Weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed